Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status

Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status

Type II endometrial cancer (EC) is responsible for most endometrial cancer-related deaths due to its aggressive nature, late-stage detection, and high tolerance to standard therapies. Thus, novel treatment strategies for type II EC are imperative. For patients with mismatch repair-deficient (dMMR) t...

Full description

Bibliographic Details
Main Authors: Kiyoka Sawada, Kentaro Nakayama, Sultana Razia, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Kosuke Kanno, Seiya Sato, Satoru Nakayama, Yoshiro Otsuki, Satoru Kyo
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Healthcare
Subjects:
endometrial cancer
type II
immune checkpoint inhibitors
deficient mismatch repair system
Online Access:https://www.mdpi.com/2227-9032/11/8/1073

Internet

https://www.mdpi.com/2227-9032/11/8/1073

Similar Items